Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2004

View Archived Issues

Statins improve outcomes in heart failure patients

Tamsulosin improves symptoms and quality of life in patients with CP/CPPS

Antiobesity drug effective against prostate cancer

11beta-Hydroxysteroid dehydrogenase inhibitor improves metabolic syndrome features

Preference for tadalafil among patients with erectile dysfunction

Aletheon acquires Pretarget intellectual property from NeoRx

NeoRx acquires rights to AMD-473 from AnorMED

SkyePharma and Medeus Pharma enter European DepoMorphine agreement

Schering AG to transfer oxybutynin incontinence ring to Barr

Array BioPharma and Takeda enter new drug discovery collaboration

Enrollment under way in phase III Periostat MR study for adult periodontitis

MediGene extends clinical development of Polyphenon E to actinic keratosis

Nycomed to develop and commercialize Oxygent in Europe

Adventrx enters definitive agreement for sale of common stock

ActivX to characterize activity of Gilead compounds

Novel histamine H3 antagonists and their use as antiobesity agents

Chiron researchers claim new pyrrole-based GSK-3 inhibitors

New gossypol analogues and their use in cancer therapy reported by CNRS

Merck KGaA team presents novel inhibitors of factor Xa and other coagulation factors

Novel small molecule tubulin inhibitor by Zentaris

Karo Bio scientists identify new thyroid receptor-beta agonists

New P-selectin antagonists and their use covered by Yamanouchi patent

Enhanced tumor cytotoxicity with novel DNA-PK inhibitor

New glucocorticoid receptor modulators discovered at Boehringer Ingelheim

New MTP inhibitors in early development at Janssen

Novel Bcl-XL antagonist effective against chemoresistant cancers in vivo

Phase II study of Puricase for severe gout begins

Ipsen enters into licensing agreement for Auxilium's Testim

Indevus and Pliva enter U.S. copromotion deal for Sanctura

Japanese launch for Viread

Vela licenses late-stage molecule for depression from Otsuka

FASgen receives NCI grant to support study of FAS inhibitors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...